



an Open Access Journal by MDPI

The Role of Antimicrobial Peptides in Tackling Antimicrobial Resistance

Guest Editors:

Dr. Francois Bedard

Faculté de pharmacie, Université
Laval, Quebec, QC, Canada

**Dr. Elizabete de Souza
Cândido**

S-Inova Biotech, Programa de
Pós Graduação em
Biotecnologia, Universidade
Católica Dom Bosco, Campo
Grande 79117900, Brazil

Deadline for manuscript
submissions:

closed (31 July 2024)

Message from the Guest Editors

Dear Colleagues,

Resolving the threat of antimicrobial resistance (AMR) is a major challenge and critical for the human race. The generation of new antibiotics has fallen since the last two decades in contrast to the emergence of new multi-resistant pathogens.

Antimicrobial peptides (AMPs) have been shown as a promising solution to this alarming situation. AMPs are small peptides with diverse structures and functions, which can be used to inhibit the growth of a wide spectrum of microorganisms including multi-resistant pathogens. Potential AMP sequences have been published in the last decade from diverse sources such as synthetic antimicrobial peptides, de novo antimicrobial peptides, hydrolyzates antimicrobial peptides, and isolated peptides from immune defences.

I would like to invite you to contribute to this Special Issue of *Antibiotics*, which will provide a valuable insight for AMPs development. The aim of this issue is to understand the antimicrobial peptides activity spectrum, mechanisms of action, and their antimicrobial resistance potency with the goal of creating a solid next generation of antimicrobials for accelerating the development and generation of new AMPs.



mdpi.com/si/164091

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi